A Study to Investigate the Effect of Ciclosporin on the Pharmacokinetics of Baricitinib (LY3009104) in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 26 Apr 2017
Price : $35 *
At a glance
- Drugs Baricitinib (Primary) ; Ciclosporin
- Indications Diabetic nephropathies; Psoriasis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 08 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Oct 2013 New trial record
- 01 Oct 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.